EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Luke J Laffin, Branko Kopjar, Carrie Melgaard, Kathy Wolski, Jessica Ibbitson, Shivani Bhikam, Matthew R Weir, Elizabeth O Ofili, Reena Mehra, James M Luther, Debbie L Cohen, Ashish Sarraju iD und 5 weitere

New England Journal of Medicine · 08.05.2025 · 392 (18) · 1813-1823

DOI: 10.1056/nejmoa2501440 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 08.05.2025. Verfasst von Luke J Laffin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland. Hauptthemen laut MEDLINE: Antihypertensive Agents, Cytochrome P-450 CYP11B2, Hypertension. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Mineralys Therapeutics, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsCytochrome P-450 CYP11B2HypertensionAgedFemaleHumansMaleMiddle AgedBlood PressureBlood Pressure Monitoring, AmbulatoryDouble-Blind MethodAldosteroneDose-Response Relationship, DrugTreatment Outcome

Substanzen

Antihypertensive AgentsCytochrome P-450 CYP11B2Aldosterone

Autor:innen und Institutionen

  • Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland.
  • Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
  • Department of Health Systems and Population Health, University of Washington, Seattle.
  • Mineralys Therapeutics, Radnor, Pennsylvania.
  • Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Department of Medicine, Morehouse School of Medicine, Atlanta.

ORCID-Profile: Ashish Sarraju, Steven E Nissen

Förderung

  • Mineralys Therapeutics, Inc

Zitieren

APA

Laffin, L. J., Kopjar, B., Melgaard, C., Wolski, K., Ibbitson, J., Bhikam, S., Weir, M. R., Ofili, E. O., Mehra, R., Luther, J. M., Cohen, D. L., Sarraju, A., Wilkinson, M. J., Flack, J. M., Rodman, D., Nissen, S. E., & Advance-HTN Investigators (2025). Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. New England Journal of Medicine, 392(18), 1813-1823. https://doi.org/10.1056/nejmoa2501440

Vancouver

Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. New England Journal of Medicine. 2025;392(18):1813-1823. doi:10.1056/nejmoa2501440

BibTeX
@article{Laffin2025,
  author = {Laffin, Luke J and Kopjar, Branko and Melgaard, Carrie and Wolski, Kathy and Ibbitson, Jessica and Bhikam, Shivani and Weir, Matthew R and Ofili, Elizabeth O and Mehra, Reena and Luther, James M and Cohen, Debbie L and Sarraju, Ashish and Wilkinson, Michael J and Flack, John M and Rodman, David and Nissen, Steven E and Advance-HTN Investigators, Advance-HTN Investigators},
  title = {Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {18},
  pages = {1813--1823},
  doi = {10.1056/nejmoa2501440}
}
Kostenlos starten →